About 80% of employer health plans don't cover GLP-1 medications like Wegovy for weight loss, though some companies are adding coverage hoping it will reduce long-term healthcare costs. Only about 20% of employers currently offer this benefit to their workers.
Posts published in “GLP-1”
A local news investigation examines the benefits and potential risks of popular GLP-1 medications like Ozempic and Wegovy, featuring patient experiences including one woman who has used the treatment for two years.
Amber achieved dramatic weight loss of 105 pounds using tirzepatide, a GLP-1 medication similar to Ozempic. Her transformation story includes details about the weight loss process and additional aesthetic treatments she received.
A new study challenges concerns that popular weight-loss drugs like Ozempic and Wegovy cause significant muscle loss. Researchers found that much of the tissue loss previously attributed to muscle may actually come from healthier reductions in liver fat and other non-muscle tissue.
Amazon is expanding its pharmacy services by adding Novo Nordisk's oral version of Ozempic to its platform. This move positions Amazon to capture more of the growing market for GLP-1 weight loss medications.
Previous research suggested that popular weight loss drugs like Wegovy and Zepbound caused people to lose too much muscle along with fat. A new study challenges this concern, finding that muscle mass loss may not be as severe as scientists initially thought.
New genetic research identified a specific gene variant that makes some people less responsive to GLP-1 weight loss drugs. People with this genetic variation may need different medications because their bodies don't process the GLP-1 hormone effectively.
A pediatric obesity researcher who studies GLP-1 weight loss drugs in children argues that needing to prescribe these medications to kids indicates broader societal failures. The opinion piece suggests we should have prevented childhood obesity rather than treating it with daily injections.